Adipokine levels and their association with clinical disease severity in patients with dengue
=============================================================================================

* Heshan Kuruppu
* W.P Rivindu H. Wickramanayake
* Chandima Jeewandara
* Deneshan Peranantharajah
* Hashini S. Colambage
* Lahiru Perera
* Laksiri Gomes
* Ananda Wijewickrama
* Graham S Ogg
* Gathsaurie Neelika Malavige

## Abstract

Adipokines have not been studied in acute dengue, despite their emerging role in inducing and regulating inflammation. Therefore, we sought to identify adipokine levels in patients with varying severities of acute dengue to understand their role in disease pathogenesis. We determined the levels of leptin, resistin, omentin, adiponectin, as well as IFNβ, and NS1 using quantitative ELISA in patients with dengue fever (DF=49) and dengue haemorrhagic fever (DHF=22) at admission (febrile phase) and at the time of discharge (recovery phase). The viral loads and serotypes of all samples were quantified using quantitative real-time RT-PCR.

Resistin levels (p =0.04) and omentin (p=0.006) levels were significantly higher in patients who developed DHF. Omentin levels in the febrile phase also correlated with the AST (Spearman’s r=0.38, p=0.001) and ALT levels (Spearman’s r=0.24, p=0.04); as well as serum leptin levels with both AST (Spearman’s r=0.27, p=0.02) and ALT (Spearman’s r=0.28, p=0.02). Serum adiponectin levels in the febrile phase did not correlate with any of the other adipokines or with liver enzymes, but inversely correlated with CRP levels (Spearman’s r=-0.31, p=0.008). Although not significant (p=0.14) serum IFNβ levels were lower in the febrile phase in those who progressed to develop DHF (median 0, IQR 0 to 39.4 pg/ml), compared to those who had DF (median 37.1, IQR 0 to 65.6 pg.ml). The data suggest that adipokines are likely to play a role in the pathogenesis of dengue, which should be further explored for the potential to be used as prognostic markers and as therapeutic targets.

Keywords
*   Adipokine
*   Omentin
*   Leptin
*   Adiponectin
*   Resistin

## Introduction

Dengue is one of the most important and rapidly emerging vector-borne diseases affecting over 195 countries globally 1. The age stratified incidence, the disability adjusted life years and deaths due to dengue have gradually increased over the last 30 years1. Due to climate change and rapid urbanization, it is predicted that the global incidence will further increase with individuals being infected with multiple dengue virus (DENV) serotypes2. It is estimated that 390 million individuals are infected by the virus annually, with 25% of these infections resulting in symptomatic dengue infections3. Although the majority of those who are infected with the DENV develop asymptomatic or mild illness, a proportion of infected individuals develop complications in the form of dengue haemorrhagic fever (DHF), including shock, severe bleeding and organ dysfunction4. Those with diabetes, obesity, hypertension and asthma are more likely to develop severe dengue and complications5-8.

Endothelial dysfunction leading to vascular leak is one of the most important factors leading to severe dengue9. Although the majority of those infected with the DENV recovery without development of endothelial dysfunction, those who develop DHF have an altered and dysfunctional immune response with high levels of inflammatory cytokines, chemokines and inflammatory lipid mediators along with high levels of immunosuppressive cytokines such as IL-1010-12. An altered and dysfunctional immune response is also seen in those who develop severe COVID-19 and influenza13, 14. The presence of metabolic diseases such as obesity, diabetes and hypertension are risk factors for development of severe COVID-19, influenza as seen with dengue15, 16. In both influenza and SARS-CoV-2 infection, antiviral responses have shown to be impaired and delayed in obese individuals17. The ongoing low grade inflammation seen in obesity and diabetes facilitates a broad proinflammatory immune response, rather than a robust antiviral response17, 18. Although both diabetes and obesity are important risk factors for development of severe dengue, the mechanisms for severe dengue in those with metabolic disease have not been studied.

Adipose tissue is an important source of adipokines, such as leptin, adiponectin and cytokines such as IL-6, MCP-1 and TNFα, which play an important role in regulation of the immune system19. While some of the adipokines such as TNFα, IL-6 and resistin are potent mediators of inflammation, adipokines such as adiponectin and omentin are known to have anti-inflammatory roles20. Patients who had severe COVID-19, were shown to have higher levels of resistin, IL-6, TNFα and reduced adiponectin/leptin ratios suggesting that adipokines are likely to play an important role in disease pathogenesis21. Serum adiponectin levels were also shown to correlate with SARS-CoV-2 receptor binding domain specific antibodies in previously infected individuals who received the BNT162b2 vaccine19. In contrast, although adiponectin is known as an anti-inflammatory adipokine, higher levels in influenza infection in elderly individuals were associated with more severe lung pathology and more severe outcomes22. Therefore, it appears that different adipokines could be playing multiple and varied roles in different virus infections.

Although both obesity and diabetes are known risk factors for development of severe dengue, their role in dengue has not been previously investigated. Currently there are no antivirals or drugs for treatment of dengue, and all dengue patients are monitored for development of complications so that timely fluid management can be initiated. In order to further understand the pathogenesis of dengue and to develop therapeutics for treatment of dengue, it would be important to understand the role of adipokines in dengue and their association with clinical disease severity, viraemia and the antiviral responses. In this study, we have measured the levels of different adipokines, interferon β, viral loads, dengue NS1 levels in patients with varying severity of dengue, during the febrile phase and at the time of discharge from hospital, to better understand the role of adipokines in dengue.

## Methods

### Patients with acute dengue

Adult patients with clinical features suggestive of an acute dengue infection were recruited from the National Institute of Infectious Disease, Sri Lanka following informed written consent. Blood samples were obtained from 71 patients, in the febrile phase (≤4 days since onset of illness) and at the time of discharge from hospital (days 7 to 8 since onset of illness). The day on which the patient first developed fever was considered as the first day of illness. All clinical symptoms and laboratory results were recorded several times of the day. Evidence of fluid leakage were assessed using an ultrasound scan to detect pleural effusions and ascites. Disease severity was classified according to the 2011 World Health Organization (WHO) dengue diagnostic criteria for dengue4. Accordingly, patients with a rise in haematocrit >20% of the baseline, or those who had ultrasound scan evidence of plasma leakage were classified as having DHF. Shock was defined as the presence of a narrowing pulse pressure of 20 mm Hg in patients with DHF. According to the above criteria, 22 were classified as having DHF and 49 patients as DF.

### Ethics approval

Ethical approval was obtained from the Ethics Review Committee of the Faculty of Medical Sciences, University of Sri Jayewardenepura (ethics application number:58/19).

### Serotyping of DENV and assessment of viral copy numbers

The presence of an acute dengue infection was confirmed in all patients using quantitative real-time PCR, and DENV serotypes and viral copy numbers were quantified. Viral RNA in serum was extracted using a QIAamp Viral RNA Mini Kit (Qiagen, USA, cat:52906) and the viral copy numbers were quantified as previously described 23. Briefly, a multiplex quantitative real-time PCR was performed using the CDC real-time PCR assay and was modified to quantify DENV. Oligonucleotide primers and a dual-labelled probe for DEN serotypes 1, 2, 3, and 4 (Life Technologies, India) were used based on published sequences.

### Quantification of adipokine levels and IFNβ levels in patients with acute dengue

Levels of leptin, resistin, adiponectin, and omentin were measured in serum stored at -80 °C using quantitative ELISA assays (Abcam, UK) according to the manufacturer’s instructions. Assays were performed in serum diluted at given ratios according to the protocol for the assessment of adipokine levels. Assays were performed according to the manufacturer’s instructions. A pre-coated IFNβ quantitative ELISA (R&D systems, DuoSet, USA) was used to measure cytokine levels, according to the manufacturer’s instructions. Adipokines and IFNβ levels were measured in serum samples obtained in the febrile phase and the samples taken at the time of discharge, and in healthy individuals. These assays were interpreted using a four-parameter logistic graph as per the protocol.

### Quantification of dengue NS1 levels in patients with acute dengue

A commercial assay was used to semi-quantitatively measure NS1 antigen levels in patient sera (PLATELIA™ DENGUE NS1 Ag). The results were interpreted as ratios according to the manufacturer’s instructions.

## Results

### Clinical and laboratory characteristics of the patients

The clinical and laboratory features of the patients with DF and DHF are shown in supplementary table 1. There were similar proportions of males in those with DF 25/49 (51.02%) and DHF 12/22 (57.14%) and the mean ages of those with DF was 31.53 years (SD± 15.20) and for DHF was 30.64 years (SD± 11.54). None of the patients with DHF developed shock or bleeding manifestations. The laboratory parameters with adipokine levels of these patients are shown in table 1.

View this table:
[Table 1:](http://medrxiv.org/content/early/2023/01/09/2023.01.06.23284269/T1)

Table 1: Adipokine and other laboratory parameters in the febrile and recovery phases in patients with acute dengue

### Adipokine levels in patients with acute dengue

Resistin, omentin, leptin, and adiponectin levels were measured in all 71 patients in samples obtained during the febrile (sample A) and at the time of discharge (sample D). Resistin levels were significantly higher in patients who proceeded to develop DHF (p=0.04) compared to those who had DF (Figure 1A). Serum omentin levels were also significantly higher (p=0.006) in those who progressed to develop DHF compared to those with DF (Figure 1B). The levels were still significantly higher at the time of discharge (p=0.03), in patients with DHF compared to DF. The omentin levels declined from the levels observed in the febrile phase by the time of discharge, which was significant in patients with DF (p=0.01). There was no difference in the leptin levels in patients with DF and DHF at any of the phases of illness (Figure 1C). Although levels of adiponectin were higher in patients who proceeded to develop DHF in the febrile phase compared to those with DF, this was not significant (Figure 1D).

![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2023/01/09/2023.01.06.23284269/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2023/01/09/2023.01.06.23284269/F1)

Figure 1: Adipokine levels in patients with acute dengue
Resistin (A), omentin (B), leptin (C), and adiponectin (D) levels were measured in patients with DF (n=49) and DHF (n=22) during the febrile and recovery phases, using a quantitative ELISA. The Wilcoxon matched pair singed-rank test was used to compare the levels of adipokines of the febrile (A sample) and the recovery phases (D sample) of patients with DF and DHF. The Mann-Whitney U test (two tailed) was used to calculate the differences in the means in the DF and DHF cohorts. The error bars indicate the median and the interquartile ranges.

Serum resistin levels during the febrile phase significantly correlated with leptin levels in the febrile phase (Spearman’s r=0.3, p=0.01, Fig 2A), with omentin levels of the febrile phase (Spearman’s r=0.35, p=0.003 Fig 2B) and with both AST (Spearman’s r=0.41, p=0.0004, Fig 2C) and ALT levels (Spearman’s r=0.28, p=0.02, Fig 2D). Omentin levels in the febrile phase also correlated with the AST (Spearman’s r=0.38, p=0.001) and ALT levels (Spearman’s r=0.24, p=0.04) as well as serum leptin levels with both AST (Spearman’s r=0.27, p=0.02) and ALT (Spearman’s r=0.28, p=0.02). Serum adiponectin levels in the febrile phase did not correlate with any of the other adipokines or with liver enzymes, but inversely correlated with CRP levels (Spearman’s r=-0.31, p=0.008) (Fig 2E).

![Figure 2:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2023/01/09/2023.01.06.23284269/F2.medium.gif)

[Figure 2:](http://medrxiv.org/content/early/2023/01/09/2023.01.06.23284269/F2)

Figure 2: Correlation adipokines with transaminase and CRP levels in patients with acute dengue.
Serum adipokine levels were measured by ELISA and liver transaminase levels and CRP levels were measured by automated biochemical analyzers during the febrile phase (n=71). Serum resistin levels were positively correlated with leptin (Spearman’s r=0.3, p=0.01) (A) and omentin (Spearman’s r=0.35, p=0.003) (B) levels during the febrile phase of infection. AST (Spearman’s r=0.41, p=0.0004) (C) and ALT levels (Spearman’s r=0.28, p=0.02) (D) were also significantly correlated with resistin levels. Adiponectin was significantly inversely correlated with CRP levels (Spearman’s r=-0.31, p=0.008 (E). The Spearman rank order correlation coefficient was used to evaluate the correlation between adipokine levels, liver transaminases and CRP levels.

As adiponectin/leptin ratio has shown to be a reliable marker of adipose tissue dysfunction, we analysed the ratios of adiponectin in the febrile phase (adiponectin A) and the leptin levels in the febrile phase (leptin A), with clinical disease severity and laboratory parameters. Although there was no difference in adiponectin A/leptin A ratios in patients with DF and DHF (p=0.26), this ratio inversely correlated with AST levels (Spearman’s r=-0.26, p=0.03) and ALT levels (Spearman’s r=-0.34, p=0.004).

9/71 patients had metabolic disease based on the presence of a past history of diabetes, hypertension or hyperlipidaemia. Although serum omentin levels were higher in patients with metabolic disease (median of 899.9 pg/ml vs 578.7 pg/ml), this was not significant (p=0.15).

### Relationship between viral loads, NS1 and adipokines

11(15.4%) of were infected with DENV1, 37 (52.1%) with DENV2 and 13 (18.3%) with DENV3. 46 (93.87%) with DF and 15 (68.18%) who progressed to develop DHF had detectable virus at the febrile phase. At the time of discharge, viraemia persisted in 22 (44.89%) in those with DF and 15 (68.18%) in those with DHF. Although not significant (p=0.07), those who had DHF were more likely to have persistent viraemia at the time of discharge (odds ratio 2.6, 95% CI 0.88 to 6.9). However, at the time of presentation or discharge, there was no difference in the viral loads between patients who progressed to develop DHF and those who had DF.

In the febrile phase NS1 antigen was positive in 30 (61.22%) with DF and 12 (54.54%) who proceeded to develop DHF. By the time of discharge, NS1 antigen was still positive in 17 (34.69%) in those with DF and 5 (22.72%) in those with DHF. Unlike as seen with the virus, the NS1 antigen was not more likely (p=0.41) to be positive in those who had DHF (odds ratio 0.55, 95% CI 0.19 to 1.6). The serum leptin levels on admission significantly and inversely correlated with the viral loads at the time of discharge (Spearman’s r=-0.31, p=0.004). None of the other adipokines showed any relationship with the viral loads or with NS1 antigen levels.

### Relationship between serum IFNβ levels with adipokines, viral loads and inflammatory mediators

Although not significant (p=0.14), serum IFNβ levels were lower in the febrile phase in those who progressed to develop DHF (median 0, IQR 0 to 39.4 pg/ml), compared to those who had DF (median 37.1, IQR 0 to 65.6 pg.ml) (Fig 3A). IFNβ levels inversely correlated with inflammatory markers such as CRP (Spearmans’s r=-0.28, p=0.03, Fig 3B) and with laboratory indicators of haemoconcentration such as the PCV (Spearman’s r=-0.35, p=0.01, Fig 3C). Although the CRP levels were higher in patients who progressed to DHF, this was not significant (p=0.32). CRP levels significantly correlated with AST (p=0.03) and ALT levels (p=0.009). The adiponectin A: leptin A ratios also inversely correlated with the CRP levels (Spearman’s r=-0.28, p=0.01).

![Figure 3:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2023/01/09/2023.01.06.23284269/F3.medium.gif)

[Figure 3:](http://medrxiv.org/content/early/2023/01/09/2023.01.06.23284269/F3)

Figure 3: Relationship between serum IFNβ levels with adipokines, viral loads and inflammatory mediators.
Serum IFNβ levels were measured in patients with DF (n=49) and DHF (n=22) during the febrile (A sample) and recovery phases (D sample), using a quantitative ELISA (A). The IFNβ levels inversely correlated with CRP (Spearmans’s r=-0.28, p=0.03) (B) and PCV (Spearman’s r=-0.35, p=0.01) (C). The Spearman rank order correlation coefficient was used to evaluate the correlation between IFNβ levels and inflammatory mediators. Wilcoxon matched pair singed-rank test was used to compare the levels of IFNβ of the febrile and the recovery phases of patients with DF and DHF. The Mann-Whitney U test (two tailed) was used to calculate the differences in the means in the DF and DHF cohorts. The error bars indicate the median and the interquartile ranges.

## Discussion

In this study we have shown that both resistin and omentin levels were significantly higher in the febrile phase in patients who progressed to develop DHF. Although leptin levels were not different at the febrile phase or discharge phase in patients with DF or DHF, leptin, resistin and omentin correlated with the AST and ALT levels, which are indicators of the extent of liver damage. We did not see any difference in the adipokine levels in those with metabolic disease compared to others, possible due to small number (n=9) of individuals who had metabolic disease. Resistin is mainly produced by monocytes, macrophages and other leucocytes and its production is shown to be stimulated by lipopolysaccharide (LPS) and cytokines such as IL-6, TNFα and IL-1β, which are all shown to be elevated during early illness in dengue24, 25. While the antiviral effects of resistin have not been studied extensively, it has been shown to induce IFNγ and also acts via TLR-4 to induce production of many proinflammatory cytokines and induce neutrophil extracellular trap formation25. We did find that the resistin levels were higher in the febrile phase in those who progressed to DHF, compared to those who had DF. However, it is not clear if resistin levels were induced by the high levels of proinflammatory cytokines which are known to be induced upon infection with the DENV and by dengue NS126, or if high resistin levels also contributed to the elevation of these cytokines.

Omentin has been considered to be an anti-inflammatory adipokine, which inversely correlated with waist circumference, dyslipidaemia, hypertension, impaired glucose tolerance and was shown to induce a protective effect against endothelial dysfunction in human umbilical vein endothelial cells27. However, in vitro studies have shown that omentin induces production of proinflammatory mediators from adipocytes and therefore is likely to contribute to obesity associated chronic inflammation27. In a study in obese individuals, it was shown that while higher serum levels of omentin-1 were associated with lower levels of IL-6 and TNFα, higher omentin was associated with IL-4, IL-13 and IL-1β, showing that different cohorts can show variable results regarding omentin levels28, 29. In contrast, lower omentin levels were seen in patients with COVID-19 and omentin was thought to reduce IL-6 and other inflammatory cytokines in COVID-1930. In our study, we found that serum omentin levels were significantly higher in patients who progressed to develop DHF compared to DF and this difference was also seen at the time of discharge. Although the role of omentin in dengue is not known, omentin (intelectin) was shown to induce allergen induced production of IL-25, IL-33 and TSLP in asthma and atopic dermatitis31. We recently showed that innate like lymphoid cells (ILC2s) were activated in dengue, were infected by the DENV and showed an impaired type I interferon signature in those who had severe disease32. Therefore, it would be important to further study a potential role of omentin in inducing IL-25 and IL-33 which in turn activate ILC2 and thereby could be contributing to severe disease. Indeed, many studies have shown that asthma and allergy are independent risk factors for development of severe dengue33.

Higher CRP levels during early illness in patients with dengue, was shown to associate with an increased risk of progression to severe disease and was also associated with hospitalization34. We found that CRP levels during early illness correlated with both AST and ALT levels, whereas serum adiponectin levels and adiponectin/leptin ratios during early illness inversely correlated with CRP levels. Adiponectin has shown to negatively correlate with highly sensitive CRP in patients with diabetes, and was also shown to inversely correlate with CRP levels following the BNT162b2 vaccine in SARS-CoV-2 infected individuals19, 35. As adiponectin inversely correlated with CRP and was correlated with the extent of the rise in liver transaminases, it is likely that this adipokine in likely to reduce inflammation and possibly immunopathogenesis in dengue, which should be further investigated.

Although not significant, patients who progressed to develop DHF had a trend to lower IFNβ levels and had prolonged viraemia when compared to those with DF. IFNβ levels also negatively correlated with CRP levels suggesting that those who progress to DHF have an impaired type I IFN response, which leads to prolonged viraemia and higher levels of inflammatory mediators. We previously showed that ILC2 had an impaired type I IFN signature in those who had severe disease and that exogenous IFNβ restored type I IFN responses in vitro infection of ILC2 with the DENV32. As many of the adipokines such as adiponectin and resistin regulate the production of immunosuppressive cytokines such as IL-10 and induce proinflammatory cytokines36, their potential role in regulating type I IFN production in DENV infection should be further investigated.

In summary, in this study we found that adipokines such as resistin and omentin were significantly elevated during early illness in those who progressed to develop DHF. Many of these adipokines correlated with liver transaminases, while adiponectin inversely correlated with CRP levels. As obesity and diabetes are important risk factors for development of severe dengue, and since they appear to play a role in the pathogenesis of severe dengue, their role should be further explored to develop therapeutic targets.

## Supporting information

Supplementary table 1 [[supplements/284269_file05.docx]](pending:yes)

## Data Availability

All data produced in the present work are contained in the manuscript.

## Acknowledgements

We are grateful to the NIH, USA (grant number 5U01AI151788-02) and the UK Medical Research Council.

*   Received January 6, 2023.
*   Revision received January 6, 2023.
*   Accepted January 9, 2023.


*   © 2023, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.Zeng Z, Zhan J, Chen L, Chen H, Cheng S. Global, regional, and national dengue burden from 1990 to 2017: A systematic analysis based on the global burden of disease study 2017. EClinicalMedicine 2021; 32:100712.
    
    

2.  2.Colon-Gonzalez FJ, Sewe MO, Tompkins AM, Sjodin H, Casallas A, Rocklov J, et al. Projecting the risk of mosquito-borne diseases in a warmer and more populated world: a multi-model, multi-scenario intercomparison modelling study. Lancet Planet Health 2021; 5:e404–e14.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2542-5196(21)00132-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom) 

3.  3.Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature 2013; 496:504–7.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nature12060&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23563266&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000317984400041&link_type=ISI) 

4.  4.WHO, ed. Comprehensive guidelines for prevention and control of dengue fever and dengue haemorrhagic fever. SEARO, New Delhi, India: World Health Organization; 2011.
    
    

5.  5.Figueiredo MA, Rodrigues LC, Barreto ML, Lima JW, Costa MC, Morato V, et al. Allergies and diabetes as risk factors for dengue hemorrhagic fever: results of a case control study. PLoS Negl Trop Dis 2010; 4:e699.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pntd.0000699&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20532230&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom) 

6.  6.Lee IK, Hsieh CJ, Lee CT, Liu JW. Diabetic patients suffering dengue are at risk for development of dengue shock syndrome/severe dengue: Emphasizing the impacts of co-existing comorbidity(ies) and glycemic control on dengue severity. J Microbiol Immunol Infect 2018.
    
    

7.  7.Tsheten T, Clements ACA, Gray DJ, Adhikary RK, Furuya-Kanamori L, Wangdi K. Clinical predictors of severe dengue: a systematic review and meta-analysis. Infect Dis Poverty 2021; 10:123.
    
    

8.  8.Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S, et al. Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis. Lancet Infect Dis 2021; 21:1014–26.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom) 

9.  9.Malavige GN, Ogg GS. Pathogenesis of vascular leak in dengue virus infection. Immunology 2017; 151:261–9.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/imm.12748&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28437586&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom) 

10. 10.Malavige GN, Jeewandara C, Ogg GS. Dysfunctional Innate Immune Responses and Severe Dengue. Front Cell Infect Microbiol 2020; 10:590004.
    
    

11. 11.Brasier AR, Ju H, Garcia J, Spratt HM, Victor SS, Forshey BM, et al. A three-component biomarker panel for prediction of dengue hemorrhagic fever. Am J Trop Med Hyg 2012; 86:341–8.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoidHJvcG1lZCI7czo1OiJyZXNpZCI7czo4OiI4Ni8yLzM0MSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzAxLzA5LzIwMjMuMDEuMDYuMjMyODQyNjkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

12. 12.Singla M, Kar M, Sethi T, Kabra SK, Lodha R, Chandele A, et al. Immune Response to Dengue Virus Infection in Pediatric Patients in New Delhi, India--Association of Viremia, Inflammatory Mediators and Monocytes with Disease Severity. PLoS Negl Trop Dis 2016; 10:e0004497.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pntd.0004497&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26982706&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom) 

13. 13.Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, et al. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci Alliance 2021; 4.
    
    

14. 14.Patel MM, York IA, Monto AS, Thompson MG, Fry AM. Immune-mediated attenuation of influenza illness after infection: opportunities and challenges. Lancet Microbe 2021; 2:e715–e25.
    
    

15. 15.Malavige GN, Jeewandara C, Ogg GS. Dengue and COVID-19: two sides of the same coin. J Biomed Sci 2022; 29:48.
    
    

16. 16.Zhao X, Gang X, He G, Li Z, Lv Y, Han Q, et al. Obesity Increases the Severity and Mortality of Influenza and COVID-19: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2020; 11:595109.
    
    

17. 17.Honce R, Schultz-Cherry S. Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution. Front Immunol 2019; 10:1071.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3389/fimmu.2019.01071&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom) 

18. 18.Perez-Galarza J, Procel C, Canadas C, Aguirre D, Pibaque R, Bedon R, et al. Immune Response to SARS-CoV-2 Infection in Obesity and T2D: Literature Review. Vaccines (Basel) 2021; 9.
    
    

19. 19.Pavel-Tanasa M, Constantinescu D, Cianga CM, Anisie E, Mereuta AI, Tuchilus CG, et al. Adipokines, and not vitamin D, associate with antibody immune responses following dual BNT162b2 vaccination within individuals younger than 60 years. Front Immunol 2022; 13:1000006.
    
    

20. 20.Fasshauer M, Bluher M. Adipokines in health and disease. Trends Pharmacol Sci 2015; 36:461–70.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.tips.2015.04.014&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26022934&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom) 

21. 21.Flikweert AW, Kobold ACM, van der Sar-van der Brugge S, Heeringa P, Rodenhuis-Zybert IA, Bijzet J, et al. Circulating adipokine levels and COVID-19 severity in hospitalized patients. Int J Obes (Lond) 2022:1–12.
    
    

22. 22.Jiang Y, Yi C, Yi Y, Jin Q, Kang AS, Li J, et al. Adiponectin exacerbates influenza infection in elderly individuals via IL-18. Signal Transduct Target Ther 2020; 5:32.
    
    

23. 23.Silva T, Jeewandara C, Gomes L, Gangani C, Mahapatuna SD, Pathmanathan T, et al. Urinary leukotrienes and histamine in patients with varying severity of acute dengue. PLoS One 2021; 16:e0245926.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0245926&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33544746&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom) 

24. 24.Shyamali NLA, Mahapatuna SD, Gomes L, Wijewickrama A, Ogg GS, Malavige GN. Risk Factors for Elevated Serum Lipopolysaccharide in Acute Dengue and Association with Clinical Disease Severity. Trop Med Infect Dis 2020; 5.
    
    

25. 25.Li Y, Yang Q, Cai D, Guo H, Fang J, Cui H, et al. Resistin, a Novel Host Defense Peptide of Innate Immunity. Front Immunol 2021; 12:699807.
    
    

26. 26.Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med 2015; 7:304ra142.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6InNjaXRyYW5zbWVkIjtzOjU6InJlc2lkIjtzOjE0OiI3LzMwNC8zMDRyYTE0MiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzAxLzA5LzIwMjMuMDEuMDYuMjMyODQyNjkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

27. 27.Niersmann C, Rohrig K, Bluher M, Roden M, Herder C, Carstensen-Kirberg M. Increased Release of Proinflammatory Proteins in Primary Human Adipocytes and Activation of the Inflammatory NFkB, p38, and ERK Pathways upon Omentin Treatment. Obes Facts 2020; 13:221–36.
    
    

28. 28.Zabetian-Targhi F, Mirzaei K, Keshavarz SA, Hossein-Nezhad A. Modulatory Role of Omentin-1 in Inflammation: Cytokines and Dietary Intake. J Am Coll Nutr 2016; 35:670–8.
    
    

29. 29.Zhou Y, Zhang B, Hao C, Huang X, Li X, Huang Y, et al. Omentin-A Novel Adipokine in Respiratory Diseases. Int J Mol Sci 2017; 19.
    
    

30. 30.Kukla M, Menzyk T, Dembinski M, Winiarski M, Garlicki A, Bociaga-Jasik M, et al. Anti-inflammatory adipokines: chemerin, vaspin, omentin concentrations and SARS-CoV-2 outcomes. Sci Rep 2021; 11:21514.
    
    

31. 31.Yi L, Cheng D, Zhang K, Huo X, Mo Y, Shi H, et al. Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis. Mucosal Immunol 2017; 10:1491–503.
    
    

32. 32.Fonseka CL, Hardman CS, Woo J, Singh R, Nahler J, Yang J, et al. Dengue virus co-opts innate type 2 pathways to escape early control of viral replication. Commun Biol 2022; 5:735.
    
    

33. 33.Pang J, Hsu JP, Yeo TW, Leo YS, Lye DC. Diabetes, cardiac disorders and asthma as risk factors for severe organ involvement among adult dengue patients: A matched case-control study. Sci Rep 2017; 7:39872.
    
    

34. 34.Vuong NL, Le Duyen HT, Lam PK, Tam DTH, Vinh Chau NV, Van Kinh N, et al. C-reactive protein as a potential biomarker for disease progression in dengue: a multi-country observational study. BMC Med 2020; 18:35.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom) 

35. 35.Al-Hamodi Z, Al-Habori M, Al-Meeri A, Saif-Ali R. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetol Metab Syndr 2014; 6:99.
    
    

36. 36.Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11:85–97.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nri2921&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21252989&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F01%2F09%2F2023.01.06.23284269.atom)